SEC Filing Summary: PerkinElmer, Inc. (Form 10-K)
Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.)
Reporting Period: Fiscal year ended December 28, 2003.
Business Overview: A leading provider of scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, and industrial markets. Operations are organized into three reporting segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. The company operates in over 125 countries with approximately 10,000 employees.
Key Financial Metrics
| Metric | 2003 (in millions) | 2002 (in millions) |
|---|---|---|
| Total Sales (Continuing Ops) | $1,535.2 | $1,505.0 |
| Operating Income | $137.3 | $24.3 |
| Net Income | $53.0 | $(151.9) |
| Diluted EPS | $0.41 | $(1.21) |
| Gross Margin | 41% | 40% |
| Operating Cash Flow | $160.4 | $114.5 |
| Total Debt (Long-term + Short-term) | $549.5 | $805.5 |
| Stockholders' Equity | $1,349.1 | $1,252.3 |
Material Changes vs. Prior Period
- Profitability Surge: Operating income increased significantly from $24.3 million in 2002 to $137.3 million in 2003. This improvement was driven by cost savings from restructuring, a $17.2 million inventory adjustment charge in 2002 that did not recur, and a net restructuring reversal of $3.5 million in 2003 compared to a $35.7 million charge in 2002.
- Segment Performance:
- Life and Analytical Sciences: Sales grew 1% to $1,003.7 million; operating profit jumped to $94.7 million from $27.4 million due to integration savings.
- Optoelectronics: Sales grew 9% to $351.8 million; operating profit turned positive at $42.2 million from a $4.0 million loss in 2002.
- Fluid Sciences: Sales declined 5% to $179.7 million; operating profit remained relatively flat at $17.9 million.
- Debt Reduction: The company significantly reduced its debt load. It retired all zero-coupon convertible debentures (approx. $157.4 million accreted value) and repaid $70 million of its term loan. Total debt decreased from $805.5 million to $549.5 million.
- Discontinued Operations: The company completed the sale of its Entertainment Lighting business and abandoned remaining assets, recording a net loss of $1.7 million. It also recorded a $2.4 million loss related to working capital adjustments on the prior sale of its Security and Detection Systems business.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management targets additional pre-tax cost savings of $5.0 million to $20.0 million in fiscal 2004 from the combination of Life Sciences and Analytical Instruments businesses, aiming for a total of $30.0 million to $45.0 million relative to 2002 levels.
- Capital Expenditures: Expected to be approximately $40 million in 2004, focused on new products, process improvements, and IT investments.
- Interest Rate Risk: A significant portion of debt is variable rate. A 10% increase in interest rates would increase pre-tax charges by approximately $1.4 million in 2004. The company entered into interest rate swaps in January 2004 to hedge $100 million of fixed-rate debt.
- Legal Contingencies:
- Enzo Biochem Litigation: Defending against allegations of patent infringement and breach of contract; filed a counterclaim alleging invalidity of Enzo's patents.
- Class Action: Defending a securities class action lawsuit regarding misleading statements; loss amount cannot be reasonably estimated.
- Environmental: Accrued $6.2 million for known environmental matters; management does not expect material additional liability.
- Market Risks: Exposure to cyclical downturns in pharmaceutical, semiconductor, and aerospace markets. International sales represent 53% of total revenue, exposing the company to foreign exchange fluctuations.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with financial ratios (interest coverage, leverage) under the Senior Secured Credit Facility and 8 7/8% Notes.
- Restructuring Savings: Monitor the realization of the targeted $30M-$45M in pre-tax cost savings from the Life and Analytical Sciences integration.
- Legal Outcomes: Track the status of the Enzo Biochem patent litigation and the securities class action lawsuit for potential material liabilities.
- Segment Mix: Assess the sustainability of the turnaround in the Optoelectronics segment and the continued weakness in biopharmaceutical demand affecting Life and Analytical Sciences.
- Foreign Exchange: Evaluate the impact of currency fluctuations on the 53% of sales generated outside the U.S.